Türk popülasyonunda Polisitemia vera hastalarında CYP 2D6*4 polimorfizmi
Amaç: Birçok çalışma, ksenobiyotiklerin biyotransformasyonundan
CYP 2D6* 4 polymorphism in Polycythemia vera patients in Turkish population
Objective: Many studies have shown the association of
___
- Tefferi A, Elliott M. Thrombosis in myeloproliferative
disorders: Prevalence, prognostic factors, and the role of
leukocytes and JAK2V617F. Semin Thromb Hemost 2007;
33:313-20. doi: 10.1055/s-2007-976165.
- Spivak JL, Barosi G, Tognoni G, et al. Chronic
myeloproliferative disorders. Hematology (Am Soc
Hematol Educ Program) 2003; 200-24. doi: 10.1182/
asheducation-2003.1.200.
- Tefferi A. Pathogenetic mechanisms in chronic
myeloproliferative disorders: polycythemia vera, essential
thrombocythemia, agnogenic myeloid metaplasia, and
chronic myelogenous leukemia. Seminars in Hematology
1999; 36:3–8.
- Bilgrami S, Greenberg, B R. Polycythemia rubra vera. Semin
Oncol 1995; 22:307-26.
- Samuelsson J. Survival in a patient with polycthemia vera
for over thirty years: implications for treatment decisions in
younger patients. Leukemia and Lymphoma 1998; 32:195-8.
doi: 10.3109/10428199809059262.
- Gonzalez FJ, Tukey RH, (editors). Drug Metabolism: How
Humans Cope with Exposure to Xenobiotics.” Goodman and
Gilman’s the Pharmacological Basis of Therapeutics. New
York, NY: McGraw-Hill, 2012.
- Guengerich FP. Cytochrome p450 and chemical toxicology.
Chem Res Toxicol 2008; 21:70-83. doi: 10.1021/tx700079z.
- Bock KW, Lilienblum W, Fischer G, et al. The role of
conjugation reactions in detoxication. Arch Toxicol 1987;
60:22-29.
- Jancova P, Anzenbacher P, Anzenbacherova E. Phase II drug
metabolizing enzymes. Biomed Pap Med Fac Univ Palacky
Olomouc Czech Repub 2010; 154:103-16.
- Abraham JE, Maranian MJ, Driver KE, et al. CYP 2D6 gene
variants: association with breast cancer specific survival in
a cohort of breast cancer patients from the United Kingdom
treated with adjuvant tamoxifen. Breast Cancer Res
2010;12:R64. doi: 10.1186/bcr2629.
- Cholerton S, Daly AK, Idle JR. The role of individual human
cytochromes P450 in drug metabolism and clinical response.
Trends Pharmacol Sci 1992; 13:434-9.
- Bertilsson L, Dahl ML, Dalén P and Al-Shurbaji A. Molecular
genetics of CYP 2D6: Clinical relevance with focus on
psychotropic drugs. Br J Clin Pharmacol 2002; 53:111-22.
doi: 10.1046/j.0306-5251.2001.01548.x.
- Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450
2D6 variants in a Caucasian population: allele frequencies
and phenotypic consequences. Am J Hum Genet 1997;
60:284-95.
- Hanioka N, Kimura S, Meyer UA, et al. The
human CYP2D locus associated with a common genetic
defect in drug oxidation: a G1934----A base change in intron
3 of a mutant CYP 2D6 allele results in an aberrant 3’ splice
recognition site. Am J Hum Genet 1990; 47:994-1001.
- Zanger UM, Schwab M. Cytochrome P450 enzymes in
drug metabolism: Regulation of gene expression,enzyme
activities, and impact of genetic variation. Pharmacology
& Therapeutics 2013; 138:103-41. doi: 10.1016/j.
pharmthera.2012.12.007.
- Bertilsson L, Dahl ML, Sjo¨qvist F, et al. Molecular basis
for rational megaprescribing inultrarapid hydroxylators of
debrisoquine. Lancet 1993; 341:63.
- Christensen РМ, Gotzsche PC, Brosen K. The sparteine/
debrisoquine (CYP 2D6) oxidation polymorphism and the
risk of lung cancer: a metaanalysis. Eur J Clin Pharmacol
1997; 51:389-93. doi: 10.1007/s002280050219.
- Taninghera M, Malacarnea D, Ugolinia A, et al. Drug
metabolism polymorphisms as modulators of cancer
susceptibility. Mutation Research/Reviews in Mutation
Research 1999; 436:227–61.
- Preston-Martin S, Pike MC, Ross RK, et al. Increased cell
division as a cause of human cancer. Cancer Res 1990;
50:7415-21.
- Schur BC, Bjerke J, Nuwayhid N, et al. Genotyping of
cytochrome P450 2D6*3 and *4 mutations using conventional
PCR*. Clinica Chimica Acta 2001; 308:25-31. doi: 10.1016/
S0009-8981(01)00422-3.
- Kim JW, Lee CG, Park YG, et al. Combined analysis
of germline polymorphisms of p53, GSTM1, GSTT1,
CYP1A1, and CYP2E1: relation to the incidence rate
of cervical carcinoma. Cancer 2000; 88:2082-91. doi:
10.1002/(SICI)1097-0142(20000501)88:9<2082::AIDCNCR14>
3.0.CO;2-D.
- Morgan GJ, Smith MT. Metabolic enzyme polymorphisms
and susceptibility to acute leukemia in adults. Am J
Pharmacogenomics 2002; 2(2).
- Hatagima, A. Genetic polymorphisms and metabolism of
endocrine disruptors in cancer susceptibility. Cad. Saúde
Pública Rio de Janeiro 2002; 18:357-77.
- Anwar WA, Abdel-Rahman SZ, El-Zein RA, et al. Genetic
polymorphism of GSTM1, CYP2E1 and CYP 2D6 in
Egyptian bladder cancer patients. Carcinogenesis 1996; 17:
1923-29.
- Caporaso NE, Tucker MA, Hoover RN, et al. Lung cancer
and the debrisoquine metabolic phenotype. J Natl Cancer Inst
1990; 82:1264-72.
- Ingelman-Sundberg M. Genetic polymorphisms of
cytochrome P4502D6 (CYP 2D6): clinical consequences,
evolutionary aspects and functional diversity, The
Pharmacogenomics J 2005; 5:6 – 13. doi:10.1038/
sj.tpj.6500285.
- Roddam PL, Rollinson S, Kane E, et al. Poor metabolizers
at the cytochrome P450 2D6 and 2C19 loci are at increased
risk of developing adult acute leukaemia, Pharmacogenetics
2000; 10:605-15.
- Worrall SF, Corrigan M, High A, et al. Susceptibility
and outcome in oral cancer: preliminary data showing an
association with polymorphism in cytochrome P450 CYP
2D6. Pharmacogenetics 1998; 8:433-9.
- Smith CA, Gough AC, Leigh PN, et al. Debrisoquine
hydroxylase gene polymorphism and susceptibility to
Parkinson’s disease. Lancet 1992; 339:1375–7.
- Sarmanova J, Benesova K, Gut I, et al. Genetic polymorphisms
of biotransformation enzymes in patients with Hodgkin’s and
non-Hodgkin’s lymphomas. Hum Mol Genet 2001;10:1265-
73.
- Aydin-Sayitoglu M, Hatirnaz O, Erensoy N, et al. Role of
CYP 2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes
in the susceptibility to acute leukemias. Am J Hematol
2006;81:162-70. doi: 10.1002/ajh.20434.
- Sailaja K, Vishnupriya S, Surekha D, et al. Association
of CYP 2D6* 4 Polymorphism with Chronic Myeloid
Leukemia. Journal of Medical Sciences Research 2007; 1(1).
- Lemos MC, Cabrita FJ, Silva HA, et al. Genetic polymorphism
of CYP 2D6, GSTM1 and NAT2 and susceptibility to
haematological neoplasias. Carcinogenesis 1999; 20: 1225-
9.
- Tayser KE, Ehsan G, Ghonemy EE, et al. Study of genetic
polymorphism of xenobiotic enzymes in acute leukemia.
Blood Coagulation and Fibrionolysis 2007; 18:489-95. doi:
10.1097/MBC.0b013e3281eec930.
- Joseph T, Kusumakkumary P, Chacko P, et al. Genetic
polymorphism of CYP1A1, CYP 2D6, GSTM1and GSTT1
and susceptibility to acute lymphoblasticleukaemia in Indian
children. Pediatric Blood Cancer 2004; 43:560 – 67. doi:
10.1002/pbc.20074.
- Krajinovic M, Labuda D, Richer C, et al. Susceptibility
to childhood acute lymphoblastic leukemia: ınfluence
of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic
polymorphisms. Blood 1999; 93: 1496-501.
- Marsh JCW, Choudry J, Parry-Jones N, et al. Study of the
association between cytochromes P450 2D6 and 2E1 genotypes
and the risk of drug and chemical induced idiosyncratic
aplastic anaemia. Br J Haematol 1999; 104:266-70.
- Zanger UM, Raimundo S, Eichelbaum M. Cytochrome
P450 2D6: overview and update on pharmacology, genetics,
biochemisry. Naunyn Schmiedebergs Arch Pharmacol 2004;
369:23-37. doi: 10.1007/s00210-003-0832-2.
- Alvan G, Bechtel P, Iselius L, et al. Hydroxylation
polymorphisms of debrisoquine and mephenytoin in
European populations. Eur J Clin Pharmacol 1990; 39:533-7.
- Aydin M, Hatirnaz O, Erensoy N, et al. CYP 2D6 and
CYP1A1 mutations in the Turkish population.Cell Biochem
Funct 2005; 23:133-5. doi: 10.1002/cbf.1222.
- Koseler A, Ilcol YO, Ulus IH. Frequency of mutated allele
CYP 2D6* 4 in the Turkish population. Pharmacology 2007;
79:203-06. doi: 10.1159/000100959.
- Aynacıoğlu AS, Sachse C, Bozkurt A. Low frequency of
defective alleles of cytochrome P450 enzymes 2C19 and
2D6 in the Turkish population. Clin Pharmacol Ther 1999;
66: 185-92. doi: 10.1053/cp.1999.v66.100072001.
- Sahin S, Aydogan L, Benli I, et al. Distribution of HLA-B27
and CYP 2D6* 4 mutations in the middle Black Sea area
(Tokat) of Turkey. Genetics and Molecular Research 2011
10:3987-91. doi: 10.4238/2011.December.2.3
- Hardy GH. Mendelian proportions in a mixed population.
Science 1908; 28:49-50. doi: 10.1126/science.28.706.49
- Rodriguez S, Gaunt TR, Day IN. Hardy–Weinberg
equilibrium testing of biological ascertainment for Mendelian
randomization studies. Am J Epidemiol 2009; 169:505-14.
doi: 10.1093/aje/kwn359.
- Anderson LA, Duncombe AS, Hughes M, et al.
Environmental, lifestyle, and familial/ethnic factors
associated with myeloproliferative neoplasms. Am J Hematol
2012 ;87:175-82. doi: 10.1002/ajh.22212.
- Ozawa S. Drug-Drug Interactions with consideration
of pharmacogenetics. Yakugaku zasshi Journal of the
Pharmaceutical Society of Japan. 2018;138:365-71. doi:
10.1248/yakushi.17-00191-5.
- Thota K, Prasad K, Basaveswara Rao MV. Detection of
cytochrome P450 polymorphisms in breast cancer patients
may ımpact on tamoxifen therapy. Asian Pac J Cancer Prev
2018 26;19:343-50. doi: 10.22034/APJCP.2018.19.2.343.